Droplite is a biotech startup that is developing a rapid, efficient point-of-care diagnostic device for both humans and animals with the potential to replace expensive ELISA tests. The technology aims to revolutionize the current diagnostics landscape by providing a swift and precise approach to evaluating diseases and assessing health conditions. This device leverages immunoassay techniques, offering a quantitative automated test that delivers accurate results within a 10-minute timeframe using just a single drop of whole blood, saliva, or urine.
The company, founded in 2019, is focused on supplanting time-intensive and costly laboratory examinations like ELISA commonly used in healthcare facilities. Notably, Droplite is not limited to human diagnostics, with plans to explore applications in veterinary medicine, allergies, food safety, and infectious diseases.
Droplite operates within the industries of Biotechnology, Health Care, and Information Technology. The startup has yet to publicly disclose details regarding its last investment and the involved investors.